Amarin | AMRN - Stock


Amarin reported $183.58M in Stock for its fiscal quarter ending in March of 2026.





Stock Change Date
AbbVie USD 5.05B 98M Mar/2026
Alnylam Pharmaceuticals USD 200.15M 117.43M Mar/2026
Amarin USD 183.58M 12.32M Mar/2026
AstraZeneca USD 6.57B 13M Mar/2026
BioCryst Pharmaceuticals USD 5.98M 587K Mar/2026
Esperion Therapeutics USD 104.21M 915K Mar/2026
GlaxoSmithKline GBP 6.16B 233M Mar/2026
Halozyme Therapeutics USD 155.47M 21.01M Mar/2026
Heron Therapeutics USD 54.57M 2.33M Dec/2022
Ionis Pharmaceuticals USD 5.56M 4.49M Mar/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Neurocrine Biosciences USD 64.5M 4.5M Mar/2026
Novartis USD 6.29B 17M Mar/2026